You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
東曜藥業(01875.HK)附屬獲科興製藥授予朴欣汀海外商業化許可
阿思達克 01-11 16:42
東曜藥業(01875.HK)公布,其全資附屬蘇州東曜與科興製藥(688136.SH)簽訂海外市場獨家商業化許可合 作協議,據此,科興製藥獲授予在除中國(包括中國、香港及澳門等地區)、歐盟(以2021年成員國為準)、英國、美國和日本以外所有國家和地區就朴欣汀(貝伐珠單抗注射液,擬使用英文商品名稱:Pusintin)的獨家商業化許可。 據此,蘇州東曜有權向科興製藥收取首付款及研發里程碑款,總計3,000萬元人民幣(下同);銷售里程碑款,最高可達3.8億元,取決於朴欣汀在合作區域內的累計淨銷售額;及銷售提成,等於朴欣汀在合作區域內的累計淨銷售額之低兩位數至高個位數百分比,按照遞減階梯式比例計算。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account